Allergic rhinitis or chronic idiopathic urticaria, seasonal allergic rhinitis. Inhibition of histamine-induced wheal & flare reactions of the skin due to allergens or medications.
Ebastine (Eba-P) is used to treat allergic conditions.
Ebastine (Eba-P) (trade names Kestine, Evastin, Ebastine (Eba-P), Aleva) is a non-sedating H1 antihistamine. It does not penetrate the blood-brain barrier and thus allows an effective block of the H1 receptor in peripheral tissue without a central side effect, i.e not causing sedation or drowsiness.
Histamine-induced wheal & flare 10 mg/day. Pruritus 10 mg/day. Severe pruritus Initially, 20 mg/day. Reduce to 10 mg/day upon improvement of itching. Allergic rhinitis or chronic idiopathic urticaria 10 mg as a single daily dose. Seasonal allergic rhinitis 20 mg/day.
Concomitant use of ketoconazole, itraconazole, clarithromycin or erythromycin may increase plasma levels of Ebastine (Eba-P) and cause QTc interval prolongation.
Nausea, Drowsiness, Abdominal pain, Dry mouth, Headache, Indigestion, Insomnia, Nose bleed, Nasal infection, Sinus inflammation, Sore throat, Weakness
Allergic conditions including rhinitis and pruritic skin disorders
Phenylephrine (Eba-P) (Phenylephrine (Eba-P)) is a decongestant that shrinks blood vessels in the nasal passages. Dilated blood vessels can cause nasal congestion (stuffy nose).
Phenylephrine (Eba-P) is used to treat nasal and sinus congestion, or congestion of the tubes that drain fluid from your inner ears, called the eustachian (yoo-STAY-shun) tubes.
Phenylephrine (Eba-P) may also be used for purposes not listed in this medication guide.
Phenylephrine (Eba-P) is used for the temporary relief of stuffy nose, sinus, and ear symptoms caused by the common cold, flu, allergies, or other breathing illnesses (e.g., sinusitis, bronchitis). This medication works by decreasing swelling in the nose and ears, thereby lessening discomfort and making it easier to breathe.
Cough-and-cold products have not been shown to be safe or effective in children younger than 6 years. Therefore, do not use this product to treat cold symptoms in children younger than 6 years unless specifically directed by the doctor. Some products (such as long-acting tablets/capsules) are not recommended for use in children younger than 12 years. Ask your doctor or pharmacist for more details about using your product safely.
Use Phenylephrine (Eba-P) as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Phenylephrine (Eba-P).
Hypotension/shock: Treatment of hypotension, vascular failure in shock. Note: Not recommended for routine use in the treatment of septic shock; use should be limited until more evidence demonstrating positive clinical outcomes becomes available (Rhodes 2017).
Cardiogenic shock: The 2017 American Heart Association (AHA) scientific statement for the Contemporary Management of Cardiogenic Shock recommends Phenylephrine (Eba-P), if needed, be considered for initial vasoactive management of cardiogenic shock due to aortic stenosis, mitral stenosis, or dynamic left ventricular outflow tract (LVOT) obstruction (AHA [van Diepen 2017]).
Hypotension during anesthesia: As a vasoconstrictor in regional analgesia
Nasal congestion: As a decongestant [OTC]
Phenylephrine (Eba-P) is a pure alpha1 agonist that will increase systemic vascular resistance without increasing heart rate or contractility. This is advantageous in patients with obstructive hypertrophic cardiomyopathy and hypotension since increases in both heart rate and contractility may cause the obstruction to worsen, leading to a decrease in cardiac output. Other vasopressors like dopamine, epinephrine, and norepinephrine may increase contractility and/or heart rate. Additional trials may be necessary to further define the role of Phenylephrine (Eba-P) in this condition.
Based on the American Urological Association guidelines for the management of priapism, due to the low risk of cardiovascular side effects intracavernous injection of Phenylephrine (Eba-P) is recommended for ischemic priapism that persists following aspiration/irrigation.
Phenylephrine (Eba-P) is a sympathomimetic amine that acts predominantly on α-adrenergic receptors. It is mainly used to treat nasal congestion, but may also be useful in treating hypotension and shock, hypotension during spinal anaesthesia, prolongation of spinal anaesthesia, paroxysmal supraventricular tachycardia, symptomatic relief of external or internal hemorrhoids, and to increase blood pressure as an aid in the diagnosis of heart murmurs.
Generic name: Phenylephrine (Eba-P) HYDROCHLORIDE 10mg in 1mL
Dosage form: injection
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
Phenylephrine (Eba-P) (Phenylephrine (Eba-P) hydrochloride) Injection, 10 mg/mL must be diluted before administration as an intravenous bolus or continuous intravenous infusion to achieve the desired concentration:
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Do not use if the solution is colored or cloudy, or if it contains particulate matter. The diluted solution should not be held for more than 4 hours at room temperature or for more than 24 hours under refrigerated conditions. Discard any unused portion.
During Phenylephrine (Eba-P) administration:
The following are the recommended dosages for the treatment of hypotension during anesthesia.
For bolus intravenous administration, prepare a solution containing a final concentration of 100 mcg/mL of Phenylephrine (Eba-P):
For continuous intravenous infusion, prepare a solution containing a final concentration of 20 mcg/mL of Phenylephrine (Eba-P) in 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP:
The Pharmacy Bulk Vial is intended for dispensing of single doses to multiple patients in a pharmacy admixture program and is restricted to the preparation of admixtures for infusion. Each closure shall be penetrated only one time with a suitable sterile transfer device or dispensing set that allows measured dispensing of the contents. The Pharmacy Bulk Vial is to be used only in a suitable work area such as a laminar flow hood (or an equivalent clean air compounding area). Dispensing from a pharmacy bulk vial should be completed within 4 hours after the vial is penetrated.
What other drugs will affect Phenylephrine (Eba-P)?
Acetaminophen: May increase the serum concentration of Phenylephrine (Eba-P) (Systemic). Monitor therapy
Alpha1-Blockers: May diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation. Monitor therapy
AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics. Monitor therapy
Benzylpenicilloyl Polylysine: Alpha1-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine. Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response. Consider therapy modification
Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics. Exceptions: Cannabidiol. Monitor therapy
Chloroprocaine: May enhance the hypertensive effect of Phenylephrine (Eba-P) (Systemic). Monitor therapy
CloZAPine: May diminish the therapeutic effect of Phenylephrine (Eba-P) (Systemic). Monitor therapy
Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use. Consider therapy modification
Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. Monitor therapy
Ergot Derivatives: May enhance the hypertensive effect of Alpha1-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha1-Agonists. Exceptions: Ergoloid Mesylates; Nicergoline. Avoid combination
FentaNYL: Alpha1-Agonists may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed. Monitor therapy
Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics. Monitor therapy
Hyaluronidase: May enhance the vasoconstricting effect of Phenylephrine (Eba-P) (Systemic). Management: Avoid the use of hyaluronidase to enhance dispersion or absorption of Phenylephrine (Eba-P). Use of hyaluronidase for other purposes in patients receiving Phenylephrine (Eba-P) may be considered as clinically indicated. Avoid combination
Iobenguane Radiopharmaceutical Products: Alpha1-Agonists may diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products. Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer these drugs until at least 7 days after each iobenguane dose. Avoid combination
Ioflupane I 123: Phenylephrine (Eba-P) (Systemic) may diminish the diagnostic effect of Ioflupane I 123. Monitor therapy
Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid. Specific dose adjustment recommendations are not presently available. Consider therapy modification
Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of Alpha1-Agonists. While linezolid is expected to interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors. Refer to linezolid specific monographs for details. Exceptions: Linezolid. Avoid combination
Ozanimod: May enhance the hypertensive effect of Sympathomimetics. Management: Concomitant use of ozanimod with sympathomimetic agents is not recommended. If combined, monitor patients closely for the development of hypertension, including hypertensive crises. Consider therapy modification
Propacetamol: May increase the serum concentration of Phenylephrine (Eba-P) (Systemic). Management: Monitor patients closely for increased side effects of Phenylephrine (Eba-P) if propacetamol is used concomitantly. Patients with underlying blood pressure issues or arrhythmias may need closer monitoring and may warrant consideration of alternative therapies. Monitor therapy
Solriamfetol: Sympathomimetics may enhance the hypertensive effect of Solriamfetol. Sympathomimetics may enhance the tachycardic effect of Solriamfetol. Monitor therapy
Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics. Monitor therapy
Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics. Monitor therapy
Tricyclic Antidepressants: May enhance the therapeutic effect of Alpha1-Agonists. Tricyclic Antidepressants may diminish the therapeutic effect of Alpha1-Agonists. Monitor therapy
What are the possible side effects of Phenylephrine (Eba-P)?
Applies to Phenylephrine (Eba-P): intravenous solution
In addition to its needed effects, some unwanted effects may be caused by Phenylephrine (Eba-P) (the active ingredient contained in Phenylephrine (Eba-P)). In the event that any of these side effects do occur, they may require medical attention.
If any of the following side effects occur while taking Phenylephrine (Eba-P), check with your doctor or nurse immediately:
Incidence not known:
If any of the following symptoms of overdose occur while taking Phenylephrine (Eba-P), get emergency help immediately:
Symptoms of overdose:
Some of the side effects that can occur with Phenylephrine (Eba-P) may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:
Incidence not known:
What is the most important information I should know about Phenylephrine (Eba-P)?
Minims Phenylephrine (Eba-P) hydrochloride should not be used in patients with severe hypertension, ventricular tachycardia, or in patients who are hypersensitive to it or to any of the components.
Ebastine/phenylephrine in India.
|Unit description / dosage (Manufacturer)||Price, USD|
|Eba-P Ebastine 10 mg, Phenylephrine10 mg. TAB / 100||$ 7.94|
|EBA-P tab 10's (Blubell)||$ 0.79|
|Eba-P Ebastine 10 mg, Phenylephrine10 mg. TAB / 100||$ 7.94|
List of Eba-P substitutes (brand and generic names):
|EBAHIST 10 MG TABLET 1 strip / 10 tablets each (Kivi Labs Ltd)||$ 0.94|
|EBAHIST 20 MG TABLET 1 strip / 10 tablets each (Kivi Labs Ltd)||$ 1.37|
|Ebahist 10mg Tablet (Kivi Labs Ltd)||$ 0.09|
|Ebahist 20mg Tablet (Kivi Labs Ltd)||$ 0.14|
|EBANORM 10MG TABLET 1 strip / 10 tablets each (Kivi Labs Ltd)||$ 0.71|
|EBANORM 20MG TABLET 1 strip / 10 tablets each (Kivi Labs Ltd)||$ 1.03|
|Ebanorm 20mg Tablet (Kivi Labs Ltd)||$ 0.10|
|EBASET 10 MG TABLET 1 strip / 10 tablets each (Kivi Labs Ltd)||$ 0.69|
|EBASET 20 MG TABLET 1 strip / 10 tablets each (Kivi Labs Ltd)||$ 0.83|
|Ebaset 10mg Tablet (Kivi Labs Ltd)||$ 0.07|
|Ebaset 20mg Tablet (Kivi Labs Ltd)||$ 0.08|
|Ebasil 10mg FC-TAB / 10 (Abbott)||$ 0.80|
|Ebasil 20mg FC-TAB / 10 (Abbott)||$ 1.13|
|EBASIL 10 MG TABLET 1 strip / 10 tablets each (Abbott)||$ 1.06|
|EBASIL 20 MG TABLET 1 strip / 10 tablets each (Abbott)||$ 1.44|
|EBASIL film-coated tab 10 mg x 10's (Abbott)||$ 0.80|
|EBASIL film-coated tab 20 mg x 10's (Abbott)||$ 1.13|
|Ebasil 10mg Tablet (Abbott)||$ 0.12|
|Ebasil 20mg Tablet (Abbott)||$ 0.16|
|Ebasitin 10 mg x 10 Blister x 10 Tablet|
|Ebast (India, Myanmar)|
|EBAST Capsule/ Tablet / 10mg / 10 units (Micro Labs)||$ 0.70|
|Ebast 10mg TAB / 10 (Micro Labs)||$ 0.87|
|Ebast 20mg TAB / 10 (Micro Labs)||$ 1.03|
|Ebast 5mg DT-TAB / 10 (Micro Labs)||$ 0.39|
|10 mg x 10's (Micro Labs)||$ 0.75|
|20 mg x 10's (Micro Labs)||$ 1.03|
|5 mg x 10's (Micro Labs)||$ 0.39|
|EBAST 10 MG TABLET 1 strip / 10 tablets each (Micro Labs)||$ 1.21|
|EBAST 10 MG TABLET DT 1 strip / 10 tablet dts each (Micro Labs)||$ 1.24|
|EBAST 20 MG TABLET 1 strip / 10 tablets each (Micro Labs)||$ 1.67|
|EBAST 5 MG SUSPENSION 1 bottle / 60 ML suspension each (Micro Labs)||$ 0.75|
|EBAST ODT 10MG TABLET 1 strip / 10 tablets each (Micro Labs)||$ 1.24|
|EBAST film-coated tab 10 mg x 10's (Micro Labs)||$ 0.87|
|EBAST film-coated tab 20 mg x 10's (Micro Labs)||$ 1.03|
|EBAST dispertab 5 mg x 10's (Micro Labs)||$ 0.39|
|Ebast FC tab 10 mg 10 x 10's (Micro Labs)|
|Ebast FC tab 20 mg 10 x 10's (Micro Labs)|
|Ebast 10mg Tablet (Micro Labs)||$ 0.14|
There are no reviews yet. Be the first to write one!
Information checked by Dr. Sachin Kumar, MD Pharmacology